Ticking a new box in enzyme chemistry
Alcresta Therapeutics’ enzyme derived product, RELiZORB®, is a significant development for patients requiring enteral nutrition who suffer from the devastating consequences of malnutrition and fat malabsorption commonly seen in tube fed patients with Cystic Fibrosis, Gastric Cancers, Pancreatitis, and other serious diseases.
Alcresta were looking for an outsourcing partner with enzyme chemistry experience. A partner who understood enzyme production, purification and immobilisation including analytical expertise. A partner who were able to take R&D projects, which involved both chemistry and biochemistry, through to commercial production and product supply.
Almac ticked all the boxes for Alcresta. You can read the full article recently showcased in Chemical & Engineering News by clicking here.
Almac API, Chemical Development, Analytical & Solid State Services
Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).
We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.
We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.
Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.